Who are CD101's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vivjoa, Brexafemme, Brexafemme, Cresemba, Jublia, Luzu.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cd101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CD101 — Competitive Intelligence Brief

CD101 (CD101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal. Area: Infectious Disease.

phase 2 Antifungal beta-glucan Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

CD101 (CD101) — Cidara Therapeutics Inc.. CD101 is a recombinant human monoclonal antibody targeting beta-glucan.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CD101 TARGET	CD101	Cidara Therapeutics Inc.	phase 2	Antifungal	beta-glucan
Vivjoa	OTESECONAZOLE	Mycovia Pharms	marketed	Azole Antifungal [EPC]	Cytochrome P450 3A4	2022-01-01
Brexafemme	IBREXAFUNGERP CITRATE	GSK	marketed	Triterpenoid Antifungal		2021-01-01
Brexafemme	IBREXAFUNGERP	GSK	marketed	Triterpenoid Antifungal		2021-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Jublia	EFINACONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2014-01-01
Luzu	LULICONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal class)

Cidara Therapeutics Inc. · 1 drug in this class
Drugs for Neglected Diseases · 1 drug in this class
Fernanda P Silveira, MD, MS · 1 drug in this class
LI YAN · 1 drug in this class
Novartis · 1 drug in this class
Polichem S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CD101 — Competitive Intelligence Brief. https://druglandscape.com/ci/cd101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab